share_log

4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T

SEC announcement ·  May 17 16:03
Summary by Moomoo AI
On May 15, 2024, Stephen T. Worland, the Chief Executive Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,806 shares of common stock at a price of $1.683 per share. Following this transaction, Worland's direct holdings in the company increased to 12,494 shares. The transaction is classified as a grant, award, or other acquisition, according to the transaction code description. In addition to his direct holdings, Worland also has an indirect beneficial ownership of 22,493 shares through a trust.
On May 15, 2024, Stephen T. Worland, the Chief Executive Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,806 shares of common stock at a price of $1.683 per share. Following this transaction, Worland's direct holdings in the company increased to 12,494 shares. The transaction is classified as a grant, award, or other acquisition, according to the transaction code description. In addition to his direct holdings, Worland also has an indirect beneficial ownership of 22,493 shares through a trust.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more